Theraclion Announces Its Half-year Financial Results for 2023 and Provides an Update on the Execution of Its Strategy - Seite 3

 

Average headcount

30

28

+7%

Accounts approved by the Board of Directors on 4 October 2023.

Theraclion SA generated sales of €981K in the first half of 2023, an increase of 183% compared to the first half of 2022. Theraclion is voluntarily reducing its commercial efforts and focusing on perfecting SONOVEIN HD treatment protocols. Theraclion expects to maintain a limited level of sales in Europe. Commercial development will be driven mainly by the US and Chinese markets, which guarantee a much faster return on investment.

In the first half of the year, Theraclion recorded the sale of a state-of-the-art device to the University of Virginia as part of a clinical trial on breast cancer research. Approved by the FDA, this pilot study aims to evaluate the combined effects of high-intensity focused ultrasound (HIFU) and conventional therapies on the immune response in patients suffering from early-stage breast cancer.

Sales of consumables rose by 65%, driven by the doubling of sales in the varicose vein indication. Theraclion has chosen to make SONOVEIN available to reference centers in order to develop treatment protocols. These centers are able to use SONOVEIN in their commercial practice, which generates revenue for Theraclion.

Operating expenses rose by 10% to €4,161k, mainly as a result of higher consumption of purchases to support the 183% growth in sales. Adjusted for purchases of goods and changes in inventories, operating expenses fell by 1% to €3,629k.

The financial result was a loss of (€65k) for the first half, mainly due to foreign exchange (€28k), losses on the liquidity contract (€24k) and interest on State-Guaranteed Loans.

Research tax credit amounted to €504k for the period, up 2% from €492k a year earlier, due to the increase in research expenditure.

The loss for the first half fell slightly by 3% to €2,476k.

In K€	30/06/2023	31/12/2022	Var. %
Treasury	9,078	2,489	+6,589
Medium-term cash position	31	31